To investigate the gene expression signature in KRAS-oncogene-driven lung cancer, we compared the differences between KRAS-mutant tumors and normal lung tissue derived from a genetically engineered mouse model (GEMM), based on expression profiling and comprehensive bioinformatics analysis. This evidence concerns the gene KRAS and lung cancer.